Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Inclusion Criteria: * Histologically confirmed breast cancer that overexpresses HER-2/NEU with evidence of metastatic disease and/or chest wall recurrence prior to randomization * HER-2/NEU overexpression is defined as 3+ HER-2 positivity as measured by immunohistochemistry OR HER-2 gene amplification as measured by fluorescent in situ hybridization (FISH, e.g. Vysis), per American Society of Clinical Oncology guidelines * NOTE: representative diagnostic tissue must be submitted for central diagnostic review for confirmation of HER-2/NEU overexpression within two weeks following patient randomization * Evaluable (measurable or non-measurable) disease is allowed if confirmed within 4 weeks prior to randomization * Prior endocrine treatment in the adjuvant or metastatic setting is allowed, provided last dose given \>= 2 weeks prior to randomization * Radiation therapy is allowed provided last dose is given \>= 3 weeks prior to randomization * Adjuvant trastuzumab therapy for breast cancer is allowed provided last dose was given \>= 12 months prior to diagnosis of recurrence * Adjuvant or neoadjuvant taxane therapy for breast cancer is allowed provided last dose was given \>= 12 months prior to diagnosis of recurrence * Adjuvant or neoadjuvant therapy with lapatinib is allowed provided last dose is given \>= 4 weeks prior to diagnosis of recurrence * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Absolute neutrophil count \>= 1,000/mm\^3 * Platelet …